



Please type a plus sign (+) inside this box

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	09/525,041
				<b>Filing Date</b>	March 14, 2000
				<b>First Named Inventor</b>	Soppet, et al.
				<b>Group Art Unit</b>	1646
				<b>Examiner Name</b>	Monshipouri, M.
<b>Sheet</b>	1	of	2	<b>Attorney Docket Number</b>	PF178D2

U.S. PATENT DOCUMENTS						Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
JK	AA	5,837,841		Bandman et al.	11-17-98		
JK	AB	5,380,645		Vogelstein	01-10-95		
JK	AC	4,683,202		Mullis	07-28-87		
JK	AD	4,584,268		Ceriani et al.,	04-22-86		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)					
Sheet	2	of	2	Attorney Docket Number	PF178D2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AG	Peter F. Mount, <i>et al.</i> , Chimeric (Mouse/Human) Anti-Colon Cancer Antibody c30.6 Inhibits the Growth of Human Colorectal Cancer Xenografts in <i>scid/scid</i> Mice, <i>Cancer Research</i> 54(23): 6160-6166 (1994),
	AH	Nicholas C. Nicolaides, <i>et al.</i> , "Mutations of two PMS homologues in hereditary nonpolyposis colon cancer," <i>Nature</i> 371:75-90 (1994)
	AI	Michael J. O'Connell, M.D., <i>et al.</i> , "Current Status of Adjuvant Chemotherapy for Colorectal Cancer," <i>CANCER Supplement</i> 70:6 (1992)
	AJ	Jagveer Singh, <i>et al.</i> , "Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis," <i>Carcinogenesis</i> 15(7):1317-1323 (1994)
	AK	M. Ueda, <i>et al.</i> , "Target Killing of Colon Cancer Cells by Immunolysin Which Recognizes CEA-Related Antigen," <i>Gastroenterology</i> 104(4):A458 (1993)
	AL	<i>Geneseq Database</i> Accession W37866; Kato, S., <i>et al.</i> "Human proteins with secretory signal sequences - used to treat immune deficiencies, infections, tumours, and haematopoietic disorders, etc." (September 13, 1996)
	AM	<i>Geneseq Database</i> Accession W37929; Bandman, <i>et al.</i> "New isolated human Reg I-gamma protein - useful for developing products for treating, e.g. diabetes, tumours or neurodegenerative disease such as Alzheimer's" (October 11, 1996)
	AN	"Quick Reference Guide," Catalog 1993-94 Edition; publ.: <i>New England Biolabs, Inc.</i> pp. 92-95 (1993)
	AO	Supplemental European Search Report dated 26.07.01 (July 26, 2001)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.